Duration of Topical Steroid Use for Psoriasis Outbreaks

Recommended Duration Based on Location and Steroid Potency

The American Academy of Dermatology recommends using topical corticosteroids for up to 4 weeks for the treatment of psoriasis outbreaks, with gradual tapering after clinical improvement 1, 2, 3
For plaque psoriasis not involving intertriginous areas, class 1 (ultrahigh-potency), class 2 (high-potency), and class 3-5 (medium-potency) topical corticosteroids should be used for up to 4 weeks 1, 4
For scalp psoriasis, class 1-7 topical corticosteroids (all potencies) are recommended for a minimum of up to 4 weeks for both initial and maintenance treatment 2, 5
For facial and intertriginous areas, lower potency corticosteroids should be used for shorter durations to minimize adverse effects 3, 4

Use of topical corticosteroids for longer than 4 weeks (up to 12 weeks) can be considered only under careful physician supervision (Level of evidence III, Strength of recommendation C) 1, 5
After clinical improvement, gradual reduction in frequency of use is recommended to minimize risk of rebound (when disease recurs more severely than before treatment) 1, 6

Ultrahigh-potency (class 1) corticosteroids show significant improvement within 2 weeks, with efficacy rates ranging from 58% to 92% 2, 4
High-potency (class 2) corticosteroids demonstrate 68-74% efficacy rates 7
Medium-potency (class 3-4) corticosteroids show 68-72% efficacy rates 7
Lower potency (class 5-7) corticosteroids have more variable efficacy rates of 41-83% 7

Local skin adverse effects include skin atrophy, striae, folliculitis, telangiectasia, and purpura 1, 8
Face, intertriginous areas, and chronically treated areas (especially forearms) are at greatest risk for adverse effects 1, 3
Topical corticosteroids may exacerbate acne, rosacea, perioral dermatitis, and tinea infections 1
Risk of hypothalamic-pituitary-adrenal axis suppression increases with prolonged use of medium to high-potency corticosteroids 8

Abrupt discontinuation of topical corticosteroids can lead to rebound flares 1, 6
Continuous use beyond 4 weeks without physician supervision increases risk of local and systemic adverse effects 1, 8
Using high-potency corticosteroids on sensitive areas (face, intertriginous regions) 3, 4
Exceeding recommended weekly amounts (for clobetasol and halobetasol, maximum weekly use should be 50g or less) 8
Failing to taper corticosteroid use after clinical improvement 1, 6